Arthritis & Rheumatology
Audio Summaries

Distinct molecular pathways supporting Sjögren's Disease clusters and disease progression

Jun 11, 2026

The authors investigate the blood transcriptomic signatures and disease progression in three distinct clusters of Sjögren's disease (SjD): B-cell active with low symptoms (BALS), high systemic activity (HSA), and low systemic activity with high symptoms (LSAHS). They find that both BALS and HSA exhibit significant interferon signaling, with BALS showing a hyperinflammatory state linked to disease progression, while HSA is characterized by pathways promoting proliferation and metabolism. These insights suggest potential mechanisms underlying disease progression in SjD and highlight the importance of distinct molecular pathways in different patient clusters.

Development and Validation of the ALARN Model: A Predictive Mortality Score for Antisynthetase Syndrome

Jun 9, 2026

The authors aimed to develop and validate a prognostic model, the ALARN score, for predicting all-cause mortality in patients with antisynthetase syndrome (ASyS). Utilizing data from 1194 patients, they identified five key prognostic factors and created a simplified scoring system that effectively stratifies patients into risk categories, demonstrating strong predictive performance in both internal and external validation cohorts. The ALARN score offers a practical tool for clinicians to assess mortality risk in ASyS patients.

Homocitrullinated Peptides Drive Pro-Inflammatory T-Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

Jun 8, 2026

The authors investigate the T-cell responses to homocitrullinated peptides (HomoCitP) in a humanized mouse model of rheumatoid arthritis (RA) to understand their potential pathogenic role. They find that immunization with HomoCitP leads to significant expansion of pro-inflammatory T helper and cytotoxic T cell subsets, along with markers of T cell exhaustion, suggesting that these responses may contribute to RA pathogenesis and could be targeted for future therapies.

Multimodal peripheral blood immunophenotyping and single cell epigenetic analysis of knee osteoarthritis reveals expansion and epigenetic dysregulation of regulatory T-cell and nonclassical monocyte populations

Jun 4, 2026

The authors aimed to characterize the peripheral blood immunophenotypes and epigenetic landscapes associated with knee osteoarthritis (OA) and its radiographic progressors. Their findings revealed significant expansions of regulatory T-cells and nonclassical monocytes in OA patients, alongside extensive epigenetic remodeling, suggesting that these immune cell changes may be influenced by age and comorbid conditions. The study highlights the complexity of immune responses in OA, indicating a shift towards quiescent, non-migratory cell states despite systemic inflammation.

Fine particulate matter constituents, ozone, and systemic lupus erythematosus: A large general-population cohort analysis with extended quantile g-computation

Jun 3, 2026

The authors aimed to determine the association between exposure to individual fine particulate matter (PM_2.5) constituents and the onset of systemic lupus erythematosus (SLE), as well as the potential modifying effect of ozone on this relationship. Their analysis of a large cohort revealed that higher levels of PM_2.5, particularly from mineral dust, were linked to increased SLE risk, with ozone also contributing to this risk, especially in low ozone environments.

Integrated Clinical and Proteomic Profiling of CD19 CAR-T Cell Therapy in Progressive Systemic Sclerosis

Jun 1, 2026

The authors aimed to characterize the clinical, immunologic, and proteomic changes associated with CD19 CAR-T cell therapy in patients with progressive systemic sclerosis. The study found that this therapy resulted in manageable safety profiles and significant clinical improvements, alongside notable changes in plasma proteins related to inflammation and fibrosis. These findings suggest that CAR-T therapy induces broad remodeling of disease-related pathways, warranting further investigation in larger cohorts.

Autoreactivity vs autoimmunity: characteristics of autoantigen-specific CD4 T-cells in rheumatoid arthritis and health

Jun 1, 2026

The authors investigate the characteristics of CD4 T cells specific for citrullinated peptides in rheumatoid arthritis (RA) compared to healthy individuals, aiming to understand the differences in autoreactivity and potential biomarkers for disease progression. They find that while autoreactive T cell frequency is similar across groups, healthy individuals exhibit more naïve T cells, whereas RA patients show features indicative of in vivo activation and cytotoxic potential. These findings suggest a maturation of autoreactivity in RA, which could inform monitoring and treatment strategies.

Human Fibroblast-Myeloid cell tissue atlas across lung, synovium, skin and heart

Jun 1, 2026

The authors aimed to characterize shared and tissue-specific myeloid and stromal cell phenotypes across lung, synovium, skin, and heart to uncover key cellular subtypes involved in pathogenic tissue activation. By analyzing single-cell RNA sequencing data from various tissues, they identified distinct and overlapping cell populations, revealing common pathogenic subsets like SPP1+ macrophages and POSTN+ fibroblasts in diseased states. Their findings enhance the understanding of the roles of myeloid and stromal cells in health and disease, potentially informing future therapeutic strategies.

The nuclear receptor TR4 orchestrates cytoskeletal organization in a Gα12/ROCK-dependent manner to promote myofibroblast differentiation and tissue fibrosis in systemic sclerosis

May 28, 2026

The authors investigate the role of the nuclear receptor TR4 in fibroblast activation and its contribution to tissue fibrosis in systemic sclerosis (SSc). They find that TR4 is upregulated in SSc and promotes myofibroblast differentiation through Gα12/ROCK-dependent cytoskeletal remodeling, suggesting that targeting TR4 could be a potential therapeutic strategy for SSc and related fibrotic diseases.

A Pragmatic Trial of a Shared Decision-Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ-SAFE Study

May 18, 2026

The HCQ-SAFE study aimed to evaluate the effectiveness of a pictogram-based shared decision-making (SDM) tool in improving hydroxychloroquine (HCQ) adherence and reducing decisional conflict among patients with systemic lupus erythematosus (SLE). The results indicated that the intervention significantly increased adherence rates by 47% among non-adherers and reduced decisional conflict to just 1% post-intervention, demonstrating its feasibility and potential benefits across diverse patient demographics.